We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Drug Target Identified for Potential Treatment of Aggressive Eye Cancer

By LabMedica International staff writers
Posted on 01 Mar 2012
Print article
The protein target for a drug already being developed to treat other diseases has now been identified with high potential as an effective target for treating childhood retinoblastoma.

The potential target was identified using an approach that also helped characterize how this eye tumor becomes particularly aggressive. The mechanism was found to involve epigenetic factors and surprisingly few genetic mutations.

The only known genetic mutations associated with childhood retinoblastoma are loss-of-function mutations in the tumor suppressor gene RB1. Bi-allelic RB1 inactivation seems to trigger retinoblastoma during fetal development. Tumors then progress very quickly, but other major factors involved were unknown.

The study, reported in the January 11, 2012, advance online edition of the journal Nature, initially involved sequencing of the complete normal and cancer genomes of four retinoblastoma patients at St. Jude's University Hospital (Memphis, TN, USA). The retinoblastoma tumor genomes contained about 15-fold fewer mutations than have been found in nearly all other cancers sequenced so far. In one patient’s tumor, RB1 was the only mutation.

These findings prompted the next part of the study: to integrate the sequencing results with tests that looked at differences in gene activity patterns in tumor versus normal tissue.

“To our surprise and excitement, what we found was that instead of cancer genes having genetic mutations, they were being epigenetically regulated differently than normal cells,” said Michael Dyer, PhD, member of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute Early Career Scientist.

The genes included the proto-oncogene SYK, a known target of drugs already in clinical trials for adults with leukemia and rheumatoid arthritis.

Surprisingly, SYK has no role in normal eye development. When SYK protein levels were checked in normal and retinoblastoma tissue, they found high levels in tumor samples but absence in normal tissue. Changes observed in the SYK gene activity probably give the retinoblastoma cell "a growth advantage or provide other key factors,” said Richard Wilson, PhD, director of The Genome Institute at Washington University (St. Louis, MO, USA) and head of the team that collaborated with the St. Jude's team led by Dyer.

When the experimental drugs were used to block SYK in human retinoblastoma cells in tissue culture or in mouse eyes, the cells died. Dr. Dyer said work is now underway to reformulate one of the experimental drugs, a SYK-inhibitor called R406, so it can be delivered directly into the eye. If successful, those efforts are expected to lead to a Phase I trial in patients.

The effort was part of a PCGP project launched in 2010 in expectation that the results will provide a foundation for the next generation of clinical care for children and adolescents battling some of the most challenging cancers.

Related Links:
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP)

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.